Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1810 studies found for:    Open Studies | "Breast Neoplasms"
Show Display Options
Rank Status Study
21 Recruiting A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients
Conditions: Taxane-induced Peripheral Neuropathy;   Chemotherapy-induced Peripheral Neuropathy (CIPN);   Early-Stage Breast Carcinoma;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions: Procedure: Immediate Acupuncture Group;   Procedure: Delayed Acupuncture Group
22 Recruiting Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Veliparib;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
23 Recruiting Olaparib and Radiotherapy in Inoperable Breast Cancer
Conditions: Locally Advanced Malignant Neoplasm;   Inflammatory Breast Carcinoma;   Triple-Negative Invasive Breast Carcinoma
Interventions: Radiation: radiotherapy;   Drug: olaparib
24 Recruiting Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That Is Locally Advanced or Metastatic
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Hormone-Resistant Breast Cancer;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Exemestane;   Drug: Entinostat;   Drug: Goserelin Acetate;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
25 Recruiting A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Conditions: Carcinoma of Breast;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation
Interventions: Drug: niraparib;   Drug: Physician's choice
26 Recruiting Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Conditions: Breast Neoplasms;   Breast Cancer;   Cancer of the Breast
Interventions: Drug: Docetaxel and Cytoxan;   Drug: Dexamethasone
27 Recruiting Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Veliparib;   Drug: Carboplatin;   Other: Fluorothymidine F-18;   Procedure: Positron Emission Tomography;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
28 Recruiting Cyclophosphamide With or Without Veliparib in Patients With Locally Advanced or Metastatic Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Veliparib;   Drug: Cyclophosphamide;   Other: Placebo;   Other: Laboratory Biomarker Analysis
29 Not yet recruiting Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
Condition: Inflammatory Breast Carcinoma
Interventions: Drug: 89Zr-bevacizumab;   Procedure: FDG-PET/CT;   Procedure: MRI scan;   Procedure: Tumor biopsies
30 Recruiting Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy
Conditions: Ductal Breast Carcinoma in Situ;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Lobular Breast Carcinoma in Situ;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer
Interventions: Behavioral: Behavioral dietary intervention;   Procedure: Therapeutic conventional surgery;   Radiation: Radiation therapy;   Other: Counseling intervention;   Procedure: Quality-of-life assessment
31 Recruiting Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery
Conditions: Ductal Breast Carcinoma in Situ;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Lobular Breast Carcinoma in Situ;   Progesterone Receptor-positive Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Procedure: quality-of-life assessment
32 Unknown  "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
Conditions: Infiltrating Duct and Lobular Carcinoma In Situ;   Invasive Lobular Breast Carcinoma;   Inflammatory Breast Carcinoma
Intervention: Drug: Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
33 Not yet recruiting A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
Conditions: Breast Cancer;   Breast Carcinoma;   Breast Tumors
Interventions: Drug: Letrozole;   Drug: palbociclib
34 Recruiting Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
Conditions: HER2/Neu Positive;   Male Breast Carcinoma;   Metastatic Malignant Neoplasm to the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Drug: Lapatinib Ditosylate;   Radiation: Whole-Brain Radiotherapy;   Other: Laboratory Biomarker Analysis
35 Recruiting Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only
Conditions: HER2/Neu Positive;   Male Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Drug: Entinostat;   Drug: Lapatinib Ditosylate;   Biological: Trastuzumab;   Other: Laboratory Biomarker Analysis
36 Recruiting BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: PI3K inhibitor BYL719;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: pharmacological studies
37 Recruiting Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients
Conditions: Anxiety Disorder;   Depression;   Ductal Breast Carcinoma in Situ;   Lobular Breast Carcinoma in Situ;   Psychosocial Effects of Cancer and Its Treatment;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Other: educational intervention;   Other: counseling intervention;   Other: psychosocial support for caregiver;   Other: questionnaire administration;   Other: laboratory biomarker analysis
38 Recruiting Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors
Conditions: Ductal Breast Carcinoma in Situ;   Lobular Breast Carcinoma in Situ;   Paget Disease of the Breast;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: docosahexaenoic acid;   Other: placebo;   Other: laboratory biomarker analysis
39 Unknown  Evaluate the Use of the Magnetic Resonance Spectroscopy in Determining if the Breast Tumor is Benign or Malignant
Condition: Breast Tumors
Intervention:
40 Recruiting Biomarker Study of Breast Tumors
Condition: Breast Tumors
Intervention: Procedure: Diagnostic tumor core biopsy

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years